| AZ | EN | RU

STATISTICS


CLINICAL FEATURES AND TREATMENT PRINCIPLES OF ALLERGIC CONJUNCTIVITS
Kurbanova N.F., Aslanova V.A., Abdiyeva Y.C., Maharramova S.M.

DOI: 10.61775/2413-3302.v2i40.07

SUMMARY
Among the clinical forms of allergic conjunctivitis most commonly observed in patients, pollinotic (seasonal) conjunctivitis continues to hold a leading position. Accurate diagnosis, as well as adequate and timely treatment, helps prevent the development of complications such as scarring of the conjunctiva and eyelids. In 49.3% of patients, prominent papillary hypertrophy regressed within 2–3 weeks during the course of treatment.The main drugs used in allergic conjunctivitis are antihistamines and medications that prevent mast cell degranulation. In addition, to prevent the development of complications in these patients, the use of nonsteroidal anti-inflammatory drugs, corticosteroids, liposomal eye drops-such as cyclosporine A and combined preparations with antibacterial and anti-inflammatory effects is considered appropriate.
Keywords: allergic conjunctivitis, clinical course, treatment

REFERENCES
  1. Майчук Д.Ю. Современные возможности терапевтического лечения аллергических конъюнктивитов. Обзор. Офтальмология. 2014; 2: 19-26.
  2. Назирова З.Р. Роль местно-воспалительного процесса и иммунного реагирования при аллергических заболеваниях глаз у детей. Медицинские новости. 2017; 2: 82-4.
  3. Abelson MB, Weintraub D. Levocabastine eye drops: a new approach for the treatment of acute allergic conjunctivitis. Eur J Ophthalmol 2014; 4 (2): 91-101. https://doi.org/10.1177/112067219400400203
  4. Bakunina N.A. A clinical experience of atopic keratoconjunctivitis treatment. Ophthalmology journal. 2014; 7 (2): 78-82. https://doi.org/10.17816/ov2014278-82
  5. Bende M, Pipkorn U. Topical levocabastine, a selective H1-antagonist in seasonal allergic conjunctivitis. Allergy 2007; 42 (51): 2-5. https://doi.org/10.1111/j.1398-9995.1987.tb00374.x
  6. Bonini St, Pierdomenico R., Bonini S. Levocabastine eye drops in vernal keratoconjunctivitis. Allergy 2013; 48: 36-41. https://doi.org/10.1177/112067219500500417
  7. Dechant K.L, Goa KL. Levocabastine: a review of its pharmacological properties and therapeutic potential as a topical antihistamine in allergic rhinitis and conjunctivitis. Drugs 2014; (41): 2-4. https://doi.org/10.1177/112067219500500417
  8. Doğan Ü., Ağca S. Investigation of possible risk factors in the development of seasonal allergic conjunctivitis. Int. J. Ophthalmol. 2018; 11 (9): 1508-13. https://doi.org/10.18240/ijo.2018.09.13
  9. Esposito S., Fior G., Mori A., Osnaghi S., Ghiglioni D. An update on the therapeutic approach to vernal keratoconjunctivitis. Paediatr. Drugs. 2016 Oct; 18 (5): 347-55. https://doi.org/10.1007/s40272-016-0185-1
  10. Gane J., Buckley R. Leukotriene receptor antagonists in allergic eye disease: a systematic review and meta analysis. J. Allergy Clin. Immunol. Pract. 2013 Jan; 1 (1): 65-74. https://doi.org/10.1016/j.jaip.2012.07.001.
  11. Kaçmaz R.O., Kempen J.H., Newcomb C., et al. Cyclosporine for ocular inflammatory diseases. Ophthalmology. 2010 Mar; 117 (3): 576-84. https://doi.org/10.1016/j.ophtha.2009.08.010.
  12. Maychuk Y.F. Allergic diseases eye. M.: Medicine, 2012; 224 p. In Russian.
  13. Mahvan T.D., Buckley W.A., Hornecker J.R. Alcaftadine for the prevention of itching associated with allergic conjunctivitis. Ann. Pharmacother. 2012 Jul-Aug; 46 (7-8): 1025-32. https://doi.org/10.1345/aph.1q755.
  14. Nebbioso M., Alisi L., Giovannetti F., Armentano M, Lambiase A. Eye drop emulsion containing 0.1 % cyclosporin (1 mg/mL) for the treatment of severe vernal keratoconjunctivitis: an evidence-based review and place in therapy. Clinical Ophthalmology. 2019; 13: 1147-55. https://doi.org/10.2147/opth.s181811
  15. Roberts G., Pfaar O., Akdis C.A., et al. Guidelines on allergen immunotherapy: allergic rhinoconjunctivitis. Allergy. 2018 Apr; 73 (4): 765-98. https://doi.org/10.1111/all.14270
  16. Sánchez J, Sánchez A, Cardona, R.Particular characteristics of atopic eczema in tropical environments. The Tropical Environment Control for Chronic Eczema and Molecular Assessment (TECCEMA) cohort study. An Bras Dermatol. 2017:92(2):177 183. https://doi.org/10.1590/abd1806-4841.20175140
  17. Solomon A. Allergic manifestations of contact lens wearing. Current opinion in allergy and clinical immunology. 2016; 16 (5): 492-7. https://doi.org/10.1097/aci.0000000000000311
  18. Tagawa Y., Namba K., Nakazono Y., Iwata D., Ishida S. Evaluating the efficacy of epinastine ophthalmic solution using a conjunctivitis allergen challenge model in patients with birch pollen allergic conjunctivitis. Allergol. Int. 2017 Apr; 66 (2): 338-43. https://doi.org/10.1016/j.alit.2016.08.011
  19. Warner J. A. Warner JO, Warner JA. Fetal and early life origins of allergy. Pediatr. Allergy Immunol. 2014:25(1):7 8. https://doi.org/10.1111/pai.12201